New Head and Neck Cancer Research from University of California Described (Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients)

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Data detailed on head and neck cancer have been presented. According to news reporting from the University of California by NewsRx journalists, research stated, "This study evaluates the potential for tumor dose escalation in recurrent head and neck cancer (rHNC) patients with automated non-coplanar volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) planning (HyperArc)." The news editors obtained a quote from the research from University of California: "Twenty rHNC patients are planned with conventional VMAT SBRT to 40 Gy while minimizing organ-at-risk (OAR) doses. They are then re-planned with the HyperArc technique to match these minimal OAR doses while escalating the target dose as high as possible. Then, we compare the dosimetry, tumor control probability (TCP), and normal tissue complication probability (NTCP) for the two plan types. Our results show that the HyperArc technique significantly increases the mean planning target volume (PTV) and gross tumor volume (GTV) doses by 10.8 ± 4.4 Gy (25%) and 11.5 ± 5.1 Gy (26%) on average, respectively.